This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
Study Type
OBSERVATIONAL
Enrollment
10,337
Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
Unnamed facility
Berlin, Germany
Change From Baseline in Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement.
Time frame: Baseline, 14 Weeks
Patient Assessment of Tolerability Using a 4-Point Scale
Patient assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported.
Time frame: 14 Weeks
Physician Assessment of Tolerability Using a 4-Point Scale
Physician assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported.
Time frame: 14 Weeks
Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks
Patients who discontinued Lumigan® prior to 14 weeks was assessed as Yes or No.
Time frame: 14 Weeks
Patients Who Will Continue Use of Lumigan® After 14 Weeks
Patients who will continue use of Lumigan® after 14 weeks was assessed as Yes or No.
Time frame: 14 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.